10:29 AM EST - NeonMind Biosciences Inc. : Provided an update from CEO Rob Tessarolo on its research and development activities, as well as its plan to further develop two of its synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder and as an aid to weight loss and its maintenance. NeonMind President and CEO Rob Tessarolo Reports: "It is a very exciting time to be in the psychedelic industry, which is undergoing rapid expansion. There is a continuous flow of new companies entering the market and each is replete with important research ideas and vying for the conditions necessary to drive growth. The growing interest in studying psychedelic substances coupled with a fresh look from regulatory agencies means some of these substances have the potential to make it to market and help those patients who need innovative new approaches in care. NeonMind Biosciences Inc.
shares C.NEON are trading up 1 cent at $0.26.
